Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Retained Earnings (2019 - 2025)

Benitec Biopharma has reported Retained Earnings over the past 7 years, most recently at -$249.0 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$249.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$249.0 million (changed N/A YoY), and the annual figure for FY2025 was -$839000.0, up 5.94%.
  • Retained Earnings reached -$249.0 million in Q4 2025 per BNTC's latest filing, down from -$237.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$738000.0 in Q3 2022 and bottomed at -$249.0 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$126.1 million (2021), compared with a mean of -$92.8 million.
  • The largest annual shift saw Retained Earnings soared 99.47% in 2024 before it plummeted 23781.27% in 2025.
  • Over 5 years, Retained Earnings stood at -$1.3 million in 2021, then grew by 29.46% to -$898000.0 in 2022, then crashed by 20084.86% to -$181.3 million in 2023, then soared by 99.45% to -$993000.0 in 2024, then tumbled by 24973.31% to -$249.0 million in 2025.
  • Business Quant data shows Retained Earnings for BNTC at -$249.0 million in Q4 2025, -$237.1 million in Q3 2025, and -$839000.0 in Q2 2025.